•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Samsung Epis Holdings (KRX: 0126Z0) reported first-quarter 2026 financial results, highlighting growth at its biosimilar business Samsung Bioepis and ongoing progress across its development pipeline and partnerships.
Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings, said Samsung Bioepis delivered “solid growth” supported by continued momentum across its biosimilar portfolio. The company added that it is strengthening its position through new global partnerships and continued portfolio expansion, while marking the 10th anniversary of the launch of its first biosimilar in Europe.
On a standalone basis, Samsung Bioepis posted revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion in the first quarter of 2026. Compared with the same period a year earlier, revenue increased by 14% (up KRW 54.3 billion) and operating profit rose by 13% (up KRW 16.1 billion).
The company said first-quarter growth exceeded its January 2025 guidance by more than 10%, reflecting stronger-than-expected performance across the business.
On a consolidated basis, Samsung Epis Holdings reported revenue of KRW 453.9 billion and operating profit of KRW 90.5 billion. The company noted that non-cash accounting adjustments, including amortization of purchase price allocation (PPA)-related development costs, are reflected in consolidated revenue and operating profit. It also referenced that consolidated revenue and operating profit were previously impacted by a consolidated revenue of KRW 251.7 billion and operating loss of KRW 63.6 billion in November and December 2025.
The company’s reported growth in standalone revenue and operating profit, alongside guidance outperformance, was attributed to stronger-than-expected performance across its business. On a consolidated basis, results were also affected by non-cash accounting adjustments related to PPA amortization of development costs.
The company included a disclaimer noting that the document contains forward-looking statements about future expectations, projections, plans, and anticipated performance, which are subject to uncertainties and may result in materially different actual outcomes.
Samsung Epis Holdings is an investment holdings company focused on biopharmaceuticals and biotechnology, aiming to maximize corporate and shareholder value through R&D and investment, and to optimize strategies for its subsidiaries, Samsung Bioepis and Epis NexLab.
Samsung Bioepis, established in 2012, is a biopharmaceutical company focused on making healthcare accessible and advancing a pipeline across immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology.
Epis NexLab was established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings and focuses on next-generation biotechnology platforms using scalable peptide-related technologies.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
